Skip to Content

Follicle stimulating hormone Disease Interactions

There are 3 disease interactions with follicle stimulating hormone:

Major

Follicle Stimulating Hormone (Includes Follicle stimulating hormone) ↔ Adrenal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Adrenal Insufficiency, Hyperadrenocorticism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction. Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction. Administration of FSH may exacerbate the condition.

References

  1. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
  2. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
Major

Follicle Stimulating Hormone (Includes Follicle stimulating hormone) ↔ Thyroid Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Hypothyroidism, Hyperthyroidism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction. FSH is composed of both an alpha and beta subunit. The amino acid sequence of the alpha subunit of FSH is identical to that of TSH. Therefore, FSH may have weak TSH receptor- binding and activation.

References

  1. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
  2. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
Major

Follicle Stimulating Hormone (Includes Follicle stimulating hormone) ↔ Tumors

Severe Potential Hazard, High plausibility

Applies to: Neoplasia -- Estrogen Dependent

The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors. FSH is required for normal sex hormone production, which may be detrimental in these patients. Patients in later reproductive life have a greater predisposition to endometrial carcinoma.

References

  1. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
  2. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.

follicle stimulating hormone drug Interactions

There are 2 drug interactions with follicle stimulating hormone

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide